Patents by Inventor Stamatina Fragkogianni

Stamatina Fragkogianni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220136069
    Abstract: The present invention relates to the field of breast cancer diagnosis and treatment. The present invention provides methods comprising a) analysing a biological sample obtained from a subject to determine the presence of target molecules representative of expression of at least two biomarkers selected from the group listed in Table 1, wherein the biological sample is a breast tissue sample or derivative thereof; and b) comparing the expression levels of the biomarkers determined in (a) with one or more reference values, wherein whether there is a difference in the expression of the biomarkers in the sample from the subject compared to the one or more reference values is indicative of a clinical indication. The invention further provides methods of treatment and kits and assays for use in the methods of the invention.
    Type: Application
    Filed: March 6, 2020
    Publication date: May 5, 2022
    Inventors: Jeff Pollard, Luca Cassetta, Stamatina Fragkogianni
  • Publication number: 20220128543
    Abstract: The present invention relates to the diagnosis, prognosis, prediction and/or treatment of cancer, for example breast cancer, lung cancer or colon cancer. The present invention provides methods of diagnosing and/or prognosing cancer, predicting efficacy of treatment for cancer, assessing outcome of treatment for cancer, assessing likelihood of metastasis and/or assessing recurrence of cancer, the methods comprising a) analyzing a biological sample obtained from a subject to determine the presence of one or more target molecules representative of expression of SIGLEC1 and/or CCL8; and b) comparing the expression level of SIGLEC1 and/or CCL8 determined in (a) with one or more reference values, wherein whether there is a difference in the expression of SIGLEC1 and/or CCL8 in the sample from the subject or not compared to the one or more reference values is indicative of a clinical indication.
    Type: Application
    Filed: March 6, 2020
    Publication date: April 28, 2022
    Inventors: Jeff Pollard, Luca Cassetta, Stamatina Fragkogianni